Tennessee Ozempic Vision Loss Lawyer: NAION Blindness Claims

This page is for Tennesseans who were taking Ozempic, Wegovy, Mounjaro or another GLP-1 drug and lost vision in one eye, usually all at once and often first noticed on waking. Maybe the lower half of the view from your right eye turned gray and stayed that way. Maybe a retina specialist in Nashville or a neuro-ophthalmologist in Memphis used the word NAION and said the damage was probably permanent.

We’re Fob & Foster Personal Injury Lawyers, a personal injury firm in Birmingham, Alabama, and we review Ozempic vision loss claims from across Tennessee by phone or video, from Johnson City to Jackson. We’ll tell you straight what the federal litigation looks like, what Tennessee’s short deadline means for you, and which records decide whether you have a case. If you searched for an Ozempic lawyer near me in Knoxville or Chattanooga and landed here, start with this: don’t let the one-year clock run out while you wait for a settlement headline.

What NAION Is and What It Does to Your Sight

NAION stands for non-arteritic anterior ischemic optic neuropathy. “Ischemic” means the tissue didn’t get enough blood. “Optic neuropathy” means damage to the optic nerve, the cable that carries what your eye sees to your brain. “Anterior” puts the damage at the front of the nerve, where it enters the back of the eye, and “non-arteritic” means inflamed arteries didn’t cause it. When blood flow there drops, the nerve head swells and some of its fibers die. They don’t grow back.

What Patients Usually Notice

• Sudden, usually painless vision loss in one eye, often discovered on waking.
• A dim or gray area, commonly covering the upper or lower half of that eye’s view.
• Colors that look washed out compared with the other eye.
• Trouble with reading, steps and curbs, or dusk driving.

How Eye Doctors Confirm It

Early on, a dilated exam usually shows a swollen optic disc; months later the disc turns pale. A visual field test maps the missing area, and optical coherence tomography (OCT) measures the nerve fiber layer. In patients over 50, doctors usually order blood tests (ESR and CRP) to rule out giant cell arteritis, which causes the “arteritic” form and is treated as an emergency. There’s no proven treatment that restores vision lost to NAION. Some people regain a little sight; many don’t.

Does Ozempic Cause Blindness? What the Studies and Regulators Say

Several large studies, though not all, have found that people on semaglutide (the drug in Ozempic, Wegovy and Rybelsus) or other GLP-1 drugs were diagnosed with NAION more often than comparable patients on other medicines. In June 2025, the safety committee of the European Medicines Agency concluded that NAION is a “very rare” side effect of semaglutide, affecting up to 1 in 10,000 people. The UK’s MHRA issued a safety update in February 2026, and Australia’s TGA added class-wide warnings in July 2026. The FDA listed NAION as a potential safety signal for the fourth quarter of 2024 and says it is “evaluating the need for regulatory action,” but as of October 2026 it has not added an NAION warning to the U.S. labels for these drugs.

Two cautions. NAION is rare to begin with; in the veterans study, the authors calculated about 10 extra cases per 10,000 GLP-1 users over three years compared with SGLT2 inhibitor users. And most NAION patients aren’t totally blind. They lose part of the sight in one eye, sometimes a large part, and that loss is usually permanent. Researchers haven’t settled on a mechanism, and Novo Nordisk and Eli Lilly deny that their drugs cause NAION.

Which GLP-1 Drugs and Companies Are Named

The brand can matter. Most of the research, and Europe’s conclusion, concern semaglutide, so Ozempic and Wegovy claims rest on the deepest evidence. The science on tirzepatide is newer; we still review Mounjaro and Zepbound claims and will tell you where the evidence stands. If you switched drugs, we need the dates for each. And if your semaglutide came from a compounding pharmacy, med spa or online weight-loss service rather than a Novo Nordisk pen, say so up front. MDL 3163 targets the brand manufacturers, and a compounded product raises a different question about who made what you injected.

Where MDL 3163 Stands in October 2026

On December 15, 2025, the Judicial Panel on Multidistrict Litigation sent the federal NAION cases to the Eastern District of Pennsylvania in Philadelphia, before Judge Karen S. Marston (JPML transfer order). The court posts its case management orders on its MDL 3163 orders page. An MDL isn’t a class action: each person files an individual lawsuit, and one judge handles pretrial work for all of them. The panel’s monthly reports show 29 pending cases in January 2026, 110 in June, 200 in August, 216 in September and 247 in October (JPML report, October 1, 2026).

What “General Causation First” Means for You

Before anyone discusses individual cases or test trials, Judge Marston will decide two threshold questions. First, whether the plaintiffs’ experts can reliably show, under Federal Rule of Evidence 702, that these drugs can cause NAION. Second, on summary judgment, whether federal preemption or the adequacy of the warnings to doctors defeats the claims. If the plaintiffs clear those hurdles, case-specific work and bellwether trials follow. If they don’t, most claims could end there. You usually won’t need to travel to Philadelphia; depositions are usually arranged near home or by video.

New Jersey State Court and the Stomach-Injury MDL

A separate multicounty NAION litigation is pending in New Jersey state court before Judge Gregg A. Padovano in Bergen County; which forum fits a Tennessee claim is a strategy call we make with co-counsel. Judge Marston also oversees MDL 3094, the GLP-1 gastroparesis, ileus and obstruction cases, which had 4,025 pending on October 1, 2026. If you had a stomach injury too, tell us.

Who May Have an Ozempic Vision Loss Claim in Tennessee

Most viable Tennessee NAION claims share these features:

• You took Ozempic, Wegovy, Rybelsus, Saxenda, Trulicity, Mounjaro or Zepbound.
• An ophthalmologist or neuro-ophthalmologist diagnosed NAION in one or both eyes.
• The vision loss began while you were on the drug or soon after stopping.
• Follow-up exams document lasting loss of acuity or visual field.
• You live in Tennessee or were prescribed the drug or injured here, and you’re inside the deadline (or there’s a fact-based argument that you are).

Diabetic retinopathy, glaucoma, cataracts and macular degeneration are different diseases and aren’t part of this litigation. If that’s your diagnosis, we’ll tell you on the first call.

How Tennessee’s One-Year Deadline Works for NAION Vision Loss

Tennessee gives you one year to file a personal injury suit, Tenn. Code Ann. § 28-3-104(a)(1). Alabama and Georgia each allow two. That short year is the most common reason good Tennessee claims are lost.

The Discovery Rule: Your Vision Loss Date Is Clear, the Connection Date Isn’t

Tennessee applies a discovery rule. The year generally runs from when you knew, or reasonably should have known, that you were injured and that someone’s conduct may have caused it. NAION announces itself, so the injury date is rarely in doubt. The fight is over when you connected the vision loss to the drug, or reasonably should have. The defense will push that date early, citing news coverage, your eye doctor’s notes and your own searches.

Say you lost vision in your left eye in March 2026, and the neuro-ophthalmologist who diagnosed NAION charted that she asked about your semaglutide. The defense will argue your year began at that visit, putting the deadline in March 2027. Now say you were diagnosed in 2024, nobody mentioned the drug, and you read about a possible link in 2025. That claim may already be at or past the line. Either way, don’t count from an FDA warning (the FDA hasn’t issued one on NAION) or from the MDL’s creation. Your clock may have started at diagnosis, so call us rather than self-calculate.

The Statute of Repose

Tennessee’s statute of repose, Tenn. Code Ann. § 29-28-103(a), generally requires suit within six years of the injury, and in any event within ten years from the date the product was first purchased for use or consumption (or one year after the product’s anticipated life expires, whichever is shorter), with narrow exceptions. For most GLP-1 users the purchases at issue are recent, so the six- and ten-year limits usually aren’t the problem. How the “anticipated life” language applies to a drug with an expiration date is less settled, so we check repose in every case.

Nothing in Philadelphia stops your Tennessee clock. MDL 3163 is a collection of individual suits, and you’re only in it if you file.

What an Eye Doctor’s Records Need to Say

In an NAION case, the ophthalmology chart is the case. We never ask a doctor to write anything untrue, and you shouldn’t either. What you can do is make sure your doctors know every GLP-1 drug you’ve taken and when you started. The strongest charts show the onset date and eye, disc swelling and later pallor, acuity and visual fields at each visit, tests ruling out giant cell arteritis, a medication list naming your GLP-1, and a written NAION diagnosis.

Diabetes, Sleep Apnea and the Other Explanations the Defense Will Offer

This is the hardest part of these cases. NAION had known risk factors long before GLP-1 drugs: a small, crowded optic disc (a “disc at risk”), diabetes, high blood pressure, obstructive sleep apnea, low blood pressure during sleep, smoking, age over 50, and some medications, including erectile dysfunction drugs like sildenafil. GLP-1 patients often have several. Novo Nordisk and Lilly will say your NAION would have happened anyway.

Risk factors don’t end a case. The law doesn’t require a perfectly healthy plaintiff, and the Hathaway study reported its higher rates within groups who already had diabetes or obesity. We look at how long you lived with each risk factor without trouble, whether it was controlled, when you started the drug or raised the dose, whether earlier eye exams showed a healthy nerve, and your CPAP use. We’d rather hear about your sleep apnea from you than from a defense lawyer.

If You Lost Vision in One Eye, the Risk to the Other Eye

NAION can strike the second eye later, and the crowded-disc anatomy behind it is often present in both eyes. Keep every follow-up visit and report any change in the good eye the same day. Talk with your eye doctor and prescriber about whether to continue the GLP-1. Do not stop or change a prescription without talking to your doctor; diabetes and obesity carry their own risks. A second-eye event also enlarges the claim and may raise its own deadline questions, so tell your lawyer right away.

Working and Driving With Vision Loss in Tennessee

Tennessee, like every state, sets minimum vision standards for a driver’s license through the Department of Safety and Homeland Security. Many people who lose sight in one eye still meet the standard with the other; some don’t, especially with a wide field loss. Commercial drivers face stricter federal standards. Whether you can drive is for your eye doctor and the state to decide, but the answer shapes what your claim is worth.

One-eye vision loss also costs depth perception. A delivery driver in Memphis, a machinist in Chattanooga or a nurse in Knoxville may find the job is no longer safe. Retirees lose things no pay stub shows, like driving to church. Keep a log of what changed and what it cost, including:

• Low-vision rehabilitation, magnifiers and screen-reading tools.
• Rides to appointments and work once you’ve stopped driving.
• Lost overtime, a lost commercial license or a forced job change.
• Ongoing exams to watch the healthy eye.

Tennessee Product Liability Law That Applies to an Ozempic Claim

The Products Liability Act and the Learned Intermediary Doctrine

Drug injury claims in Tennessee fall under the Tennessee Products Liability Act, Tenn. Code Ann. § 29-28-101 et seq. The central theory here is failure to warn. Tennessee follows the learned intermediary doctrine, Pittman v. Upjohn Co. (Tenn. 1994): the manufacturer’s warning duty runs to the prescribing doctor, so the case asks what Novo Nordisk and Lilly told physicians and when, and whether a proper warning would have changed what your doctor did. U.S. labels still say nothing about NAION while European regulators have treated it as a semaglutide side effect since June 2025.

Comparative Fault

Under modified comparative fault, McIntyre v. Balentine (Tenn. 1992), you can recover if you’re less than 50% at fault, and your award drops by your share. It plays a smaller role in warning cases than after a wreck, but expect arguments that you kept injecting after symptoms began or skipped follow-up care.

Damage Caps and Why They Bite in Vision Cases

Tennessee caps noneconomic damages (pain, suffering, loss of enjoyment of life) at $750,000, or $1,000,000 for catastrophic losses as the statute defines them, Tenn. Code Ann. § 29-39-102. The cap matters more in an NAION case than in most. With no proven treatment, the medical bills are often modest; most of the harm is the loss of sight itself, of independence, and the fear for the other eye. The catastrophic tier is limited to a short statutory list: spinal cord injury causing paraplegia or quadriplegia, amputation of two hands, two feet or one of each, severe third-degree burns, and the wrongful death of a parent of a minor child. Vision loss, even in both eyes, is not on that list, so NAION claims will generally be measured against $750,000. The cap has narrow exceptions, such as when a defendant intentionally falsified, destroyed or concealed records to evade liability. Economic damages (medical bills, lost earnings, future care) aren’t capped, which matters for someone who loses a commercial license or trade. Punitive damages are generally capped at the greater of twice compensatory damages or $500,000, Tenn. Code Ann. § 29-39-104. That statute also generally bars punitive damages against the maker of an FDA-approved drug made and labeled as approved, unless the company withheld material information from the FDA or misrepresented it.

If the Person With the Claim Has Died

NAION isn’t fatal, so wrongful death claims are uncommon here. If someone with a claim has died, the right to pursue it passes to the surviving spouse, children or next of kin under Tenn. Code Ann. §§ 20-5-106, -107 and -113, generally within the same one-year limit.

What Affects the Value of a Tennessee Ozempic Vision Loss Claim

No GLP-1 vision case has settled or reached a verdict, so anyone quoting an “average Ozempic settlement” is guessing. Value, if these claims resolve, will turn on:

• How much vision you lost, and whether one eye or both.
• Documented permanence on follow-up testing.
• How tightly the timeline ties the drug to the loss.
• Which drug you took.
• Your other risk factors and how well they were controlled.
• Your age, your work and whether you drove for a living.
• Economic losses, Tennessee’s noneconomic cap, and the general causation ruling in Philadelphia, which affects every case at once.

Filing on time comes first. A late claim is generally worth nothing.

If You Lost Vision on a GLP-1 Drug: What to Do This Week

1. Write down the date your vision changed, which eye, and what you saw. Add the drug, dose and date of your last dose increase.
2. Keep your eye appointments and tell your prescriber about the diagnosis. Don’t stop or change the medicine without talking to that doctor.
3. Ask your pharmacy for a printed fill history covering every GLP-1 you’ve used.
4. Request your eye records, including visual field printouts and OCT images.
5. Keep any pen carton with its label and lot number.
6. Stay off social media about your eyes and medication; defense lawyers use posts to argue your deadline started earlier.
7. Call (205) 407-6009 before the year runs.

Ozempic Vision Loss Litigation Updates

October 20, 2026 – Master Complaint Due October 28 With 247 Cases Pending

The JPML’s October 1 report listed 247 actions in MDL 3163, up from 216 a month earlier, and 4,025 in the companion GI MDL 3094. The Master Complaint is due October 28. No trial date or settlement exists.

August 27, 2026 – Judge Marston Sets the Discovery and Expert Schedule

CMO 14 closes fact discovery for Lilly on December 18, 2026 and for Novo Nordisk on February 26, 2027. Plaintiffs’ experts are due March 26, 2027; Rule 702 and summary judgment motions July 2, 2027.

July 2, 2026 – Court Orders General Causation to Go First

CMO 12 put general causation and warning adequacy ahead of everything else and deferred bellwether selection.

December 15, 2025 – JPML Creates MDL 3163

The panel centralized the federal cases before Judge Karen S. Marston, naming Ozempic, Wegovy, Saxenda and Trulicity.

Talk to a Tennessee Ozempic Vision Loss Lawyer Today

Fob & Foster Personal Injury Lawyers is a personal injury firm at 2226 1st Ave S, Suite 105, in Birmingham, Alabama. We review GLP-1 vision loss claims from anywhere in Tennessee, including Nashville, Memphis, Knoxville, Chattanooga, Clarksville, Murfreesboro, Franklin, Jackson and Johnson City, by phone or video, and we work alongside national co-counsel who are litigating these mass torts.

A free review starts with when your vision changed, which drug you took, and what your eye doctor diagnosed. We’ll tell you whether your claim fits MDL 3163, where your Tennessee deadline likely stands, and which records we need. There is no fee unless we recover for you.

Call (205) 407-6009 or toll-free (866) 837-1010, or send us your question online. With a one-year clock, the sooner we see your dates, the more options you keep.

Related Practice Areas

• Ozempic Vision Loss Lawsuit in Alabama
• Ozempic Vision Loss Lawsuit in Georgia
• Dupixent Lawsuit in Tennessee
• Tennessee Histoplasmosis Outbreak Claims
• Defective Product Claims